Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
May 07 2024 - 8:55AM
Ipsen S.A. - Formalities for making available and consulting
preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of
the Combined Shareholders’ Meeting of 28 May 2024 of Ipsen
S.A.
- Formalities for making available
and consulting preparatory documents to the Meeting
BOULOGNE-BILLANCOURT, FRANCE, 7 May 2024
- The Shareholders of the Company are invited to
participate in the Combined Shareholders’ Meeting of Ipsen
(Euronext: IPN; ADR: IPSEY) to be held on Tuesday 28 May 2024
at 3:00 p.m. (Paris time) at the Salons de l'Hôtel des Arts et
Métiers, 9 bis avenue d'Iéna, 75116 Paris.
The preliminary notice of the Meeting (“avis de
réunion”) was published in the Bulletin des Annonces Légales
Obligatoires (BALO) of 17 April 2024 and the notice of Meeting
(“avis de convocation”) was published in the BALO on 6 May 2024.
These documents, as well as the Convening notice (including the
agenda, the draft resolutions and the conditions regarding
attendance and vote), are also available on Ipsen’s website at the
following address: www.ipsen.com, under the
Investors / Regulated
Information / Shareholders Meeting section. Documents and
information relating to this Meeting are made available to
shareholders under the legal and regulatory conditions in
force.
The Shareholders will be asked to approve in
particular the following resolutions:
- The payment of a dividend of €1.20
per share for the 2023 financial year, the ex-date being set on
30 May 2024 and the dividend payment on 3 June 2024;
- The renewal of the terms of office
of BEECH TREE S.A. and Mrs. Carol XUEREF as Directors for a term of
4 years as well as the ratification of the temporary appointment of
Mr. Pascal TOUCHON as a Director, maintaining the independence
Directors’ rate within the Board of Directors at a third in
accordance with the Afep-Medef Code and each gender’s proportion at
more than 40% in accordance with the law (Directors representing
the employees being not taken into account in these rates).
In accordance with applicable regulatory
provisions:
- Registered shareholders may, up to
the fifth day (inclusive) before the Meeting, request from the
Company to send these documents, where appropriate at his/her
express request by electronic means. For holders of bearer shares,
the exercise of this right is subject to the presentation of a
shareholding certificate (attestation de participation) in the
bearer securities accounts managed by the authorized
intermediary.
- Any shareholder may consult these
documents at the Company’s headquarters.
About Ipsen
We are a global biopharmaceutical company with a
focus on bringing transformative medicines to patients in three
therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by external innovation
and supported by nearly 100 years of development experience and
global hubs in the U.S., France and the U.K. Our teams in more than
40 countries and our partnerships around the world enable us to
bring medicines to patients in more than 80 countries.
Ipsen is listed in Paris (Euronext: IPN) and in
the U.S. through a Sponsored Level I American Depositary Receipt
program (ADR: IPSEY). For more information, visit ipsen.com.
Ipsen contacts
Investors
- Craig
Marks | + 44 (0) 7584 349 193
-
Nicolas Bogler | + 33 (6) 52 19 98 92
Media
- Amy
Wolf | + 41 7957 607 23
- Ioana
Piscociu | + 33 (6) 69 09 12 96
Disclaimers and/or Forward-Looking
StatementsThe forward-looking statements, objectives and
targets contained herein are based on Ipsen’s management strategy,
current views and assumptions. Such statements involve known and
unknown risks and uncertainties that may cause actual results,
performance or events to differ materially from those anticipated
herein. All of the above risks could affect Ipsen’s future ability
to achieve its financial targets, which were set assuming
reasonable macroeconomic conditions based on the information
available today. Use of the words ‘believes’, ‘anticipates’ and
‘expects’ and similar expressions are intended to identify
forward-looking statements, including Ipsen’s expectations
regarding future events, including regulatory filings and
determinations. Moreover, the targets described in this document
were prepared without taking into account external-growth
assumptions and potential future acquisitions, which may alter
these parameters. These objectives are based on data and
assumptions regarded as reasonable by Ipsen. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain
risks and uncertainties, notably the fact that a promising medicine
in early development phase or clinical trial may end up never being
launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. Ipsen must face or might
face competition from generic medicine that might translate into a
loss of market share. Furthermore, the research and development
process involves several stages each of which involves the
substantial risk that Ipsen may fail to achieve its objectives and
be forced to abandon its efforts with regards to a medicine in
which it has invested significant sums. Therefore, Ipsen cannot be
certain that favorable results obtained during preclinical trials
will be confirmed subsequently during clinical trials, or that the
results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the medicine concerned. There can be
no guarantees a medicine will receive the necessary regulatory
approvals or that the medicine will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements. Other risks
and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including
interest rate and currency exchange rate fluctuations; the impact
of pharmaceutical industry regulation and healthcare legislation;
global trends toward healthcare cost containment; technological
advances, new medicine and patents attained by competitors;
challenges inherent in new-medicine development, including
obtaining regulatory approval; Ipsen’s ability to accurately
predict future market conditions; manufacturing difficulties or
delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of Ipsen’s patents
and other protections for innovative medicines; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Ipsen also depends on third parties to develop and market some of
its medicines which could potentially generate substantial
royalties; these partners could behave in such ways which could
cause damage to Ipsen’s activities and financial results. Ipsen
cannot be certain that its partners will fulfil their obligations.
It might be unable to obtain any benefit from those agreements. A
default by any of Ipsen’s partners could generate lower revenues
than expected. Such situations could have a negative impact on
Ipsen’s business, financial position or performance. Ipsen
expressly disclaims any obligation or undertaking to update or
revise any forward-looking statements, targets or estimates
contained in this press release to reflect any change in events,
conditions, assumptions or circumstances on which any such
statements are based, unless so required by applicable law. Ipsen’s
business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des
Marchés Financiers. The risks and uncertainties set out are not
exhaustive and the reader is advised to refer to Ipsen’s latest
Universal Registration Document, available on ipsen.com.
- Documents availability - 2024 Ipsen Combined Shareholder's
Meeting
Ipsen (EU:IPN)
Historical Stock Chart
From Apr 2024 to May 2024
Ipsen (EU:IPN)
Historical Stock Chart
From May 2023 to May 2024